HRP20180295T1 - Postupci za proizvodnju suspenzije aripiprazola i formulacija osušena smrzavanjem - Google Patents

Postupci za proizvodnju suspenzije aripiprazola i formulacija osušena smrzavanjem Download PDF

Info

Publication number
HRP20180295T1
HRP20180295T1 HRP20180295TT HRP20180295T HRP20180295T1 HR P20180295 T1 HRP20180295 T1 HR P20180295T1 HR P20180295T T HRP20180295T T HR P20180295TT HR P20180295 T HRP20180295 T HR P20180295T HR P20180295 T1 HRP20180295 T1 HR P20180295T1
Authority
HR
Croatia
Prior art keywords
suspension
aripiprazole
pulverization
sterile
particle size
Prior art date
Application number
HRP20180295TT
Other languages
English (en)
Croatian (hr)
Inventor
Shogo Hiraoka
Takakuni Matsuda
Junichi Hatanaka
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39816777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180295(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20180295T1 publication Critical patent/HRP20180295T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HRP20180295TT 2007-07-31 2008-07-30 Postupci za proizvodnju suspenzije aripiprazola i formulacija osušena smrzavanjem HRP20180295T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007200088 2007-07-31
PCT/JP2008/064076 WO2009017250A1 (en) 2007-07-31 2008-07-30 Methods for producing aripiprazole suspension and freeze-dried formulation
EP08792242.3A EP2170279B1 (en) 2007-07-31 2008-07-30 Methods for producing aripiprazole suspension and freeze-dried formulation

Publications (1)

Publication Number Publication Date
HRP20180295T1 true HRP20180295T1 (hr) 2018-03-23

Family

ID=39816777

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180295TT HRP20180295T1 (hr) 2007-07-31 2008-07-30 Postupci za proizvodnju suspenzije aripiprazola i formulacija osušena smrzavanjem

Country Status (27)

Country Link
US (7) US9457026B2 (OSRAM)
EP (1) EP2170279B1 (OSRAM)
JP (1) JP4879349B2 (OSRAM)
KR (1) KR101546106B1 (OSRAM)
CN (1) CN101801342B (OSRAM)
AR (2) AR067747A1 (OSRAM)
CA (1) CA2695178C (OSRAM)
CO (1) CO6290634A2 (OSRAM)
CY (1) CY1120165T1 (OSRAM)
DK (1) DK2170279T3 (OSRAM)
ES (1) ES2661037T3 (OSRAM)
HR (1) HRP20180295T1 (OSRAM)
HU (1) HUE036214T2 (OSRAM)
IL (2) IL244186A0 (OSRAM)
LT (1) LT2170279T (OSRAM)
MX (1) MX2010001311A (OSRAM)
MY (1) MY152789A (OSRAM)
NO (1) NO2170279T3 (OSRAM)
NZ (1) NZ582415A (OSRAM)
PL (1) PL2170279T3 (OSRAM)
PT (1) PT2170279T (OSRAM)
RU (1) RU2483711C2 (OSRAM)
SI (1) SI2170279T1 (OSRAM)
TW (1) TWI410255B (OSRAM)
UA (1) UA97286C2 (OSRAM)
WO (1) WO2009017250A1 (OSRAM)
ZA (1) ZA201000307B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
AR082494A1 (es) * 2010-08-24 2012-12-12 Otsuka Pharma Co Ltd Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona
LT2667856T (lt) * 2011-01-24 2021-11-25 Otsuka Pharmaceutical Co., Ltd. Medicininė priemonė, kurioje yra sausos masės kompozicija, apimanti aripiprazolą kaip veikliąją sudedamąją dalį, ir sausos masės kompozicija, apimanti aripiprazolą kaip veikliąją sudedamąją dalį
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
KR101103011B1 (ko) * 2011-10-13 2012-01-05 (주)일신오토클레이브 스크루 형 고압 발생 장치
CN102524261B (zh) * 2011-12-16 2014-12-03 辽宁师范大学 一种强力生根剂纳米制剂、其制备方法及应用
CN102450269A (zh) * 2011-12-27 2012-05-16 辽宁师范大学 三唑酮纳米胶体悬浮剂及其制备方法
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
WO2014002553A1 (ja) * 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
US9655951B2 (en) * 2013-01-23 2017-05-23 Cartilast II LLC Preservation of the biological activity of undenatured type II collagen
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
AU2017303975A1 (en) 2016-07-28 2019-03-21 Mylan Laboratories Ltd, Process for preparing sterile aripiprazole formulation
US10821200B2 (en) * 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
CN108938578A (zh) * 2017-05-25 2018-12-07 万全万特制药（厦门）有限公司 阿立哌唑分散片及其制备方法
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
CN115364049A (zh) * 2021-05-18 2022-11-22 苏州恩华生物医药科技有限公司 一种月桂酰阿立哌唑混悬剂的制备方法
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
CN117281784B (zh) * 2023-11-24 2024-02-27 山东则正医药技术有限公司 一种阿立哌唑注射剂及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
CA2044706C (en) 1990-06-15 2003-02-25 Michael Midler Jr. Crystallization method to improve crystal structure and size
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
CN1188171C (zh) 1994-06-02 2005-02-09 廓德伦特控股剑桥有限公司 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
EP0941066B1 (en) 1996-08-26 2003-10-29 Transgene S.A. Cationic lipid-nucleic acid complexes
US6297231B1 (en) 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
CN1303278B (zh) * 1998-03-30 2010-06-23 斯凯伊药品加拿大公司 制备水不溶性物质微粒的组合物和方法
ATE355856T1 (de) 1998-07-30 2007-03-15 Point Biomedical Corp Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
ATE541565T1 (de) * 1999-05-27 2012-02-15 Khoury George F El Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
JP2001187735A (ja) 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
WO2001058428A1 (en) 2000-02-10 2001-08-16 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
AU5101801A (en) 2000-03-27 2001-10-08 Scripps Research Inst Inhibition of angiogenesis and tumor growth
AU5711501A (en) 2000-04-20 2001-11-07 Rtp Pharma Inc Improved water-insoluble drug particle process
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
CN100350977C (zh) 2001-06-14 2007-11-28 大塚制药株式会社 药物组合物
DE60224293T2 (de) 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040258757A1 (en) 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
UA79984C2 (en) 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
JP2006513236A (ja) * 2002-12-31 2006-04-20 ネクター セラピューティクス 不溶性活性物質を伴う医薬製剤
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
MXPA06004489A (es) 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
WO2005041897A2 (en) 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
US20050220887A1 (en) * 2004-01-20 2005-10-06 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
RU2412686C2 (ru) * 2004-03-23 2011-02-27 Новартис Аг Фармацевтические композиции
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
EP1858855B2 (en) * 2005-03-17 2021-03-03 Synthon B.V. Process of making crystalline type ii aripiprazole
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007053904A1 (en) 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
PT2170279T (pt) * 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada

Also Published As

Publication number Publication date
CN101801342A (zh) 2010-08-11
MY152789A (en) 2014-11-28
US20180185358A1 (en) 2018-07-05
CA2695178C (en) 2015-06-23
RU2009149820A (ru) 2011-09-10
IL244186A0 (en) 2016-04-21
PT2170279T (pt) 2018-04-06
US20200246333A1 (en) 2020-08-06
KR20100057020A (ko) 2010-05-28
LT2170279T (lt) 2018-03-12
PL2170279T3 (pl) 2018-05-30
TW200922636A (en) 2009-06-01
US20250302826A1 (en) 2025-10-02
AU2008283251A1 (en) 2009-02-05
RU2483711C2 (ru) 2013-06-10
US20100196486A1 (en) 2010-08-05
US20210361646A1 (en) 2021-11-25
JP4879349B2 (ja) 2012-02-22
EP2170279B1 (en) 2017-12-27
NZ582415A (en) 2012-05-25
US20170035752A1 (en) 2017-02-09
AR067747A1 (es) 2009-10-21
IL244231A0 (en) 2016-04-21
AR117941A2 (es) 2021-09-08
CA2695178A1 (en) 2009-02-05
UA97286C2 (ru) 2012-01-25
HUE036214T2 (hu) 2018-06-28
MX2010001311A (es) 2010-04-21
NO2170279T3 (OSRAM) 2018-05-26
SI2170279T1 (en) 2018-04-30
JP2010535151A (ja) 2010-11-18
WO2009017250A1 (en) 2009-02-05
US20240139177A1 (en) 2024-05-02
DK2170279T3 (en) 2018-03-12
CO6290634A2 (es) 2011-06-20
ES2661037T3 (es) 2018-03-27
BRPI0815382A2 (pt) 2015-02-10
KR101546106B1 (ko) 2015-08-20
EP2170279A1 (en) 2010-04-07
ZA201000307B (en) 2011-04-28
TWI410255B (zh) 2013-10-01
CN101801342B (zh) 2012-07-11
CY1120165T1 (el) 2018-12-12
US9457026B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
HRP20180295T1 (hr) Postupci za proizvodnju suspenzije aripiprazola i formulacija osušena smrzavanjem
Pietsch Agglomeration processes: phenomena, technologies, equipment
EP0925293B1 (en) Method of producing an extruded nutritional supplement product
Ketterhagen et al. Process modeling in the pharmaceutical industry using the discrete element method
Qv et al. Preparation of lutein microencapsulation by complex coacervation method and its physicochemical properties and stability
HRP20192064T1 (hr) Formulacije apiksabana
Zhang et al. Material properties of partially pregelatinized cassava starch prepared by mechanical activation
TW200740888A (en) Use of polymer powder produced from a dispersion in a shaping process, and moldings produced from this polymer powder
Chitu et al. Wet granulation in laboratory-scale high shear mixers: Effect of chopper presence, design and impeller speed
WO2009001710A1 (ja) 球状銅微粉及びその製造方法
SA517390343B1 (ar) كريات سماد مع كبريت مُمكرن
JP2015532126A (ja) 微細藻類粉顆粒及びその調製方法
CN105494956A (zh) 一种畜禽饲料加工工艺及加工设备
US20180258005A1 (en) Coated Fertilizer Compositions with a Biodegradable Coating Matrix
Levoguer Using laser diffraction to measure particle size and distribution
SI2492284T1 (en) HYDROXYCARCULULOSE MICROELECTRONICS
EP3230347B1 (de) Polymerzusammensetzung für selektive sinterverfahren
Wang et al. Influence of fluidized bed jet milling on structural and functional properties of normal maize starch
CN105315022A (zh) 一种干法工艺的腐植酸盐造粒方法
JP7245637B2 (ja) アロエ抽出物の製造方法
JP2009503156A5 (OSRAM)
CN102277238A (zh) 一种颗粒状含mes组合物
JPH0413019B2 (OSRAM)
CN104829275A (zh) 一种液体海藻肥的生产工艺及液体海藻肥
CN101804378A (zh) 能获得高产品得率的聚乙烯醇微粉形干粉的生产工艺